MC2R
ENSG00000185231
Target class
GPCR
Chromosome
18
Approved drugs
4
Clinical candidates (approved and in development)
4
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Other names
- ACTHR
- Target name
- MC2R
- Gene name
- Melanocortin 2 receptor
- Gene symbol
- MC2R
- Protein name
- Adrenocorticotropic hormone receptor (ACTH receptor) (ACTH-R) (Adrenocorticotropin receptor) (Melanocortin receptor 2) (MC2-R)
- Gene biotype
- Protein coding
- Gene family
- Melanocortin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 44.59
- Tissue specificity (Gini)
- 0.98
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:4158
- Protein interaction confidence
- 0.878417
- Protein interaction partners
- 24
- R-HSA-375276
- R-HSA-418555
- R-HSA-5579031
- End position
- 13915707
- Start position
- 13882043
- Chromosome
- 18
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 19535343
- PubMed 21862608
- PubMed 36588120
- Tissue specificity (tau)
- 0.999281
- Expression inequality (Gini)
- 0.979657
Expression in transcripts per million
- Adrenal Gland
- 44.59
- Pituitary
- 1.15
- Testis
- 0.53
- Prostate
- 0.01
- Kidney - Medulla
- 0.01
Expression in transcripts per million
- Adrenal Gland44.59
- Pituitary1.15
- Testis0.53
- Prostate0.01
- Kidney - Medulla0.01
- Esophagus - Mucosa0
- Bladder0
- Thyroid0
- Brain - Hypothalamus0
- Skin - Sun Exposed (Lower leg)0
- Skin - Not Sun Exposed (Suprapubic)0
- Small Intestine - Terminal Ileum0
- Minor Salivary Gland0
- Artery - Coronary0
- Cervix - Ectocervix0
- Esophagus - Gastroesophageal Junction0
- Heart - Left Ventricle0
- Kidney - Cortex0
- Liver0
- Cells - EBV-transformed lymphocytes0
- Artery - Aorta0
- Breast - Mammary Tissue0
- Pancreas0
- Esophagus - Muscularis0
- Brain - Nucleus accumbens (basal ganglia)0
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007187
- GO:0007189
- GO:0031948
Cellular components
- GO:0005886
- GO:0004977
- GO:0004978
- GO:0005515
regulation of transcription factor activity
Studies
- cell-based: ATG_GPCR_MC2R_TRANS is one of 35 assay component(s) measured or calculated from the ATG_GPCR assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
Biological samples
- HepG2, cell line
Evidence source
Related records
Trials (147)
- (ACTH) for the Treatment of Sarcoid Uveitis
- A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis
- A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
- A Novel Approach to Infantile Spasms
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
- A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
- A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
- A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
- A Trial of Neuroprotection With ACTH in Acute Optic Neuritis
- A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines
- ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
- ACTH for Fatigue in Multiple Sclerosis Patients
- ACTH Gel Therapy in Rheumatoid Arthritis
Drugs (4)
- Corticotropin Melanocortin receptor 2 agonist
- Corticotropin zinc hydroxide Melanocortin receptor 2 agonist
- Cosyntropin Melanocortin receptor 2 agonist
- Seractide acetate Melanocortin receptor 2 agonist